The degree of dyslipidemia associated with ART varies greatly, both between and within drug classes and depending on the co-existence of other metabolic abnormalities such as HIV-associated ...

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

Endocr Pract 12: 159–164 In clinical practice, a combination of drugs is often used to treat patients with dyslipidemia who are not achieving their treatment goals. Ezetimibe reduces LDL ...

The FDA approved olezarsen (Tryngolza) as the first drug for adults with familial chylomicronemia syndrome, a rare genetic ...

[133] Several classes of drugs are available for the management of dyslipidemia.